Core Viewpoint - Libang Pharmaceutical (Jiangsu) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and HTSC acting as joint sponsors [1] Company Overview - Libang Pharmaceutical is a global leader in biopharmaceuticals focused on the kidney disease sector, possessing the most comprehensive innovative product portfolio for kidney diseases, addressing a wide range of indications [4] - The chronic kidney disease (CKD) market is substantial, valued at several hundred billion dollars, presenting significant growth potential [4] - The company has established a vertically integrated platform encompassing research and development, production, and commercialization [4] Product Pipeline - The company has shifted from focusing solely on hyperphosphatemia to a broader range of kidney diseases, aiming to meet unmet medical needs for patients affected by kidney diseases [4] - As of October 27, 2025, the product pipeline includes seven candidate products (three in clinical stages) and one commercialized product [4] - The core product, AP301, is a potential best-in-class phosphate binder for treating hyperphosphatemia, having completed Phase III clinical trials in China and currently undergoing global Phase III trials [4] Financial Performance - For the fiscal years ending December 31, 2023, and 2024, and the six months ending June 30, 2024, and 2025, the company reported revenues of approximately 6.525 million, 1.2112 million, and 12.112 million RMB respectively [6] - Research and development expenditures for the same periods were approximately 307.461 million, 235.367 million, and 110.061 million RMB [6] - The company reported a pre-tax loss of 365.256 million RMB for 2023, 335.130 million RMB for 2024, and 209.662 million RMB for the six months ending June 30, 2025 [7]
礼邦医药递表港交所 核心产品AP301已完成中国III期注册临床试验
Zhi Tong Cai Jing·2025-10-31 13:28